Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $675,000.00 in Stock

01:08am, Friday, 24'th Dec 2021 Dakota Financial News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Edward M. Md Kaye sold 15,000 shares of the stock in a transaction on Thursday, December 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. []

Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK)

07:56am, Thursday, 23'rd Dec 2021 ETF Daily News
Equities researchers at Oppenheimer started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating and a $55.00 price target on the biopharmaceutical companys stock. Oppenheimers price target indicates a potential upside of 24.94% from the companys current price. CYTK has been the subject [] The post Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) appeared first on ETF Daily News .

Cytokinetics (NASDAQ:CYTK) Hits New 1-Year High on Analyst Upgrade

06:10pm, Wednesday, 22'nd Dec 2021 Transcript Daily
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $62.00 to $69.00. HC Wainwright currently has a buy rating on the stock. Cytokinetics traded as high as $43.70 and last traded at $43.70, with a volume of 10808 shares traded. The []
JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure
JPMorgan Chase & Co. started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a research note issued to investors on Friday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $58.00 target price on the biopharmaceutical companys stock. Several other equities research analysts have also recently commented on CYTK. Mizuho boosted their []

Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag

03:21pm, Friday, 10'th Dec 2021 Zacks Investment Research
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.5%. The SMA treatment market is growing at a signifi
Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 29,166 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was sold at an average price of $36.49, for a total value of $1,064,267.34. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Fady []
FDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM FDA Granted Designation for the Treatment of Symptomatic Obstructive Hy
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome Acadia Pharmaceuticals Inc. (N
Zacks Investment Research lowered shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports. According to Zacks, Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or []
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE